Cascade Biologics, Inc. – Trademark Portfolio
Entity Type: 03
Cascade Biologics, Inc. has 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO). Notable registered marks include EPILIFE and SYNTH-A-FREEZE. The portfolio includes 2 registered trademarks. Filings span 4 Nice Classification classes, led by Class 1 (Chemicals) and Class 9 (Computers & Electronics). This trademark owner is based in Portland, OR.
4475 SW Scholls Ferry Road
Suite 201
Portland, OR 97225
Showing of trademarks Trademarks
Trademark Classifications
Cascade Biologics, Inc.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Cascade Biologics, Inc. have?
Cascade Biologics, Inc. has 9 U.S. trademarks filed with the USPTO. Of these, 2 registered, 4 abandoned, 3 cancelled.
What trademark classes does Cascade Biologics, Inc. file in?
Cascade Biologics, Inc. files trademarks across 4 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Cascade Biologics, Inc.'s most well-known trademarks?
Cascade Biologics, Inc.'s registered trademark portfolio includes well-known marks such as EPILIFE and SYNTH-A-FREEZE. These are among 2 currently registered trademarks in the portfolio.
What is Cascade Biologics, Inc.'s trademark registration success rate?
Cascade Biologics, Inc. has a 22% trademark registration rate, with 2 out of 9 resolved applications resulting in successful registration. Currently, 0 applications are pending review.